AngioDynamics beat on sales and beat on earnings this morning -- sort of. The company reported a smaller-than-expected ...

Full Year 2025 Results Key Financial Results Revenue: US$292.5m (down 3.8% from FY ...

Fintel reports that on July 16, 2025, Lake Street initiated coverage of AngioDynamics (NasdaqGS:ANGO) with a Buy ...

Q4 2025 Earnings Call Transcript July 15, 2025 AngioDynamics, Inc. beats earnings expectations. Reported EPS is $-0.03, expectations were $-0.13. Operator: Good morning, and welcome to the ...

A Capital Region manufacturer expects to continue growing its revenue over the next year, though its bottom line could take a ...

Gain insights into AngioDynamics' Q4 2025 earnings, highlighting 12% revenue growth, international expansion, Med Tech advances, and a strong FY26 outlook.

Analysts estimate that AngioDynamics will report an earnings per share (EPS) of $-0.12. Investors in AngioDynamics are eagerly awaiting the company's announcement, hoping for news of surpassing ...

AngioDynamics expects full-year results to range from a loss of 35 cents per share to a loss of 25 cents per share, with revenue in the range of $305 million to $310 million. AngioDynamics shares have ...

Medical technology company AngioDynamics Inc is bucking what it calls an "extraordinary" effort by a rival company to recover hundreds of thousands of dollars in legal costs following its win at ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vasc.